Colorectal cancer, one of the most frequent types of cancer worldwide, has a high mortality rate. Irinotecan (CPT-11) has been approved for the treatment of advanced or metastatic disease either as a single agent or, more commonly, as part of combined chemotherapeutic regimens. Treatment with irinotecan is often accompanied by severe toxicity (e.g. neutropenia and diarrhea) that can result in treatment interruption or cessation, thus jeopardizing the patient’s prognosis and quality of life. Irinotecan is bioactivated into its metabolite SN-38, which is subsequently detoxified by uridine diphosphate-glucuronosyl transferases (mainly UGT1A1). Further, ABC transporters (i.e. ABCB1, ABCC1–ABCC6, and ABCG2) are responsible for drug efflux into bile and urine whereas OATP transporters (SLCO1B1) enable its influx from blood into hepatocytes. Genetic polymorphisms in these enzymes/pumps may result in increased systemic SN-38 level, directly correlating with toxicity. Contemporary research is focused on the clinical implementation of genetic screenings for validated gene variations prior to treatment onset, allowing tailored individual doses or treatment regimens.
FerlayJSoerjomataramIErvikMDikshitREserSMathersC.GLOBOCAN 2012 v 1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. XI, International Agency for Research on Cancer, Lyon, France, 2013, http://globocan.iarc.fr (accessed 24 October 2017).
2.
DušekLMužíkJKubásekMKoptíkováJŽaloudíkJVyzulaR.Epidemiologie zhoubných nádorů v České republice, Masarykova univerzita, 2005, cit. 2014-08-19, Verze 7.0, 2007, http://www.svod.cz (accessed 24 October 2017).
3.
AdamRDelvartVPascalGValeanuA, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg2004; 240: 644–657.
4.
LabiancaRPessiMAZamparelliG.Treatment of colorectal cancer: current guidelines and future prospects for drug therapy. Drugs1997; 53: 593–607.
5.
De GramontAFigerASeymourM, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol2000; 18: 2938–2947.
6.
DouillardJYCunninghamDRothAD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet2000; 355: 1041–1047.
7.
TournigandCAndréTAchilleE, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol2004; 22: 229–237.
8.
AndréTBoniCNavarroM, et al. Improved overall survival with oxaliplatin, fluorouracil and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol2009; 27: 3109–3116.
9.
SaltzLBNiedzwieckiDHollisD, et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol2007; 25: 3456–3461.
10.
Van CutsemELabiancaRBodokyG, et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol2009; 27: 3117–3125.
11.
YchouMRaoulJLDouilliardJY, et al. A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802). Ann Oncol2009; 20: 674–680.
12.
DelbaldoCYchouMZawadiA, et al. Postoperative irinotecan in resected stage II-III rectal cancer: analysis of the French R98 Intergroup trial. Ann Oncol2015; 26: 1208–1215.
13.
GagneJFMontminyVBelangerPJournaultKGaucherGGuillemetteC.Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol Pharmacol2002; 62: 608–617.
14.
WallaceBDWangHLaneKT, et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science2010; 330: 831–835.
15.
MichaelMBrittainMNagaiJ, et al. Phase II study of activated charcoal to prevent irinotecan-induced diarrhea. J Clin Oncol2004; 22: 4410–4417.
16.
HumerickhouseRLohrbachKLiLBorsonWFDolanME.Characterization of irinotecan hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res2000; 60: 1189–1192.
17.
MarshSXiaoMYuJ, et al. Pharmacogenomic assessment of carboxylesterases 1 and 2. Genomics2004; 84: 661–668.
18.
MathijssenRHvan AlphenRJVerweijJ, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res2001; 7: 2182–2194.
19.
HaazMCRichéCRivoryLPRobertJ.Biosynthesis of an aminopiperidino metabolite of irinotecan (7-ethyl-10-[4-(1-piperidino) piperidino] carbonyloxycamptothecine) by human hepatic microsomes. Drug Metab Dispos1998; 26: 769–774.
20.
ZhouSChanEPanSQHuangMLeeEJ.Pharmacokinetic interactions of drugs with St John’s wort. J Psychopharmacol2004; 18: 262–276.
21.
Van EsHHBoutALiuJ, et al. Assignment of the human UDP glucuronosyl-transferase gene (UGT1A1) to chromosome region 2q37. Cytogenet Cell Genet1993; 63: 114–116.
22.
VogelAKneipSBarutA, et al. Genetic link of hepatocellular carcinoma with polymorphisms of the UDP-glucuronosyl-transferase UGT1A7 gene. Gastroenterology2001; 121: 1136–1144.
23.
BarbierOGiraradHInoueY, et al. Hepatic expression of the UGT1A9 gene is governed by hepatocyte nuclear factor 4alpha. Mol Pharmacol2005; 67: 241–249.
24.
JinnoHSaekiMSaitoY, et al. Functional characterization of human UDP-glucuronosyltransferase 1A9 variant, D256N, found in Japanese cancer patients. J Pharmacol Exp Ther2003; 306: 688–693.
25.
WallaceBDWangHLaneKT, et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science2010; 330: 831–835.
26.
StrassburgCP.Hyperbilirubinemia syndromes (Gilbert-Meulengracht, Crigler-Najar, Dubin-Johnson and Rotor syndrome). Best Pract Res Clin Gastroenterol2010; 24: 555–571.
27.
BosmaPJChowdhuryRJBakkerC, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert’s syndrome. N Engl J Med1995; 333: 1171–1175.
28.
IyerLKingCDWhitingtonPF, et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest1998; 101: 847–854.
29.
BeutlerEGelbartTDeminaA.Racial variability in the UDP-glucuronosyltransferase 1 (UGT11) promoter: a balanced polymorphism for regulation of bilirubin metabolism?Proc Natl Acad Sci USA1998; 95: 8170–8174.
30.
JinnoHTanaka-KagawaTHaniokaN, et al. Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D. Drug Metab Dispos2003; 31: 108–113.
31.
MarschSMcLeodHL.Pharmacogenetics of irinotecan toxicity. Pharmacogenomics2004; 5: 835–843.
32.
De JongFAScott-HortonTJKroetzDL, et al. Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein. Clin Pharmacol Ther2007; 81: 42–49.
33.
YoshinoTArnoldDTaniguchiH, et al. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS. Ann Oncol2018; 29: 44–70.
34.
HoskinsJMGoldbergRMQuPIbrahimJGMcLeodHL.UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst2007; 99: 1290–1295.
35.
HuZYYuQPeiQGuoC.Dose-dependent association between UGT1A1*28 genotype and irinotecan-induced neutropenia: low doses also increase risk. Clin Cancer Res2010; 16: 3832–3842.
36.
LiuXChengDKuangQLiuGXuW.Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians. Pharmacogenomics J2014; 14: 120–129.
37.
HuZYYuQZhaoYS.Dose-dependent association between UGT1A1*28 polymorphism and irinotecan-induced diarrhoea: a meta-analysis. Eur J Cancer2010; 46: 1856–1865.
38.
HanJYLimHSYooYK, et al. Associations of ABCB1, ABCC2 and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer. Cancer2007; 110: 138–147.
39.
HanJYLimHSParkYHLeeSYLeeJS.Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer. Lung Cancer2009; 63: 115–120.
40.
AkiyamaYFujitaK-iIshidaH, et al. Association of ABCC2 genotype with efficacy of first-line FOLFIRI in Japanese patients with advanced colorectal cancer. Drug Metab Pharmacokinet2012; 27: 325–335.
41.
FujitaK-iNagashimaFYamamotoW, et al. Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI). Biol Pharm Bull2008; 31: 2137–2142.
42.
RhodesKEZhangWYangD, et al. ABCB1, SLCO1B1 and UGT1A1 gene polymorphisms are associated with toxicity in metastatic colorectal cancer patients treated with first-line irinotecan. Drug Metabolism Letters2007; 1: 23–30.
43.
SanoffHKMcLeodHL.Predictive factors for response and toxicity in chemotherapy: pharmacogenomics. Semin Colon Rectal Surg2008; 19: 226–230.
44.
Van CutsemECervantesAAdamR, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol2016; 27: 1386–1422.
45.
Van KuilenburgABVrekenPAbelingNG, et al. Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiency. Hum Genet1999; 104: 1–9.
46.
PremawardhenaAFischerCALiuY, et al. The global distribution of length polymorphisms of the promoters of the glucuronosyltransferase 1 gene (UGT1A1): hematologic and evolutionary implications. Blood Cells Mol Dis2003; 31: 98–101.
